BiotechTube
Hepta

Hepta

Cambridge, United States· Est.
hepta.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Hepta is an AI-native diagnostics company founded in 2021, based in Cambridge, USA, with a focus on decoding liver biology from blood. Its core technology is a liquid biopsy platform that analyzes epigenetic signatures in cell-free DNA, paired with advanced machine learning, to non-invasively detect and monitor metabolic liver disease, specifically MASH. The company aims to address critical gaps in the current diagnostic pathway, which relies on invasive biopsies or scarce imaging, by providing a scalable blood test designed for early intervention. Led by a team with expertise in liquid biopsy, AI, and hepatology, Hepta is building a platform intended to expand into other serious chronic diseases.

Metabolic DiseaseHepatology

Technology Platform

Liquid biopsy-native AI platform that interprets epigenetic patterns (e.g., DNA methylation) in cell-free DNA from blood to provide non-invasive, tissue-level insights into organ biology, starting with liver inflammation and fibrosis.

Opportunities

The massive, under-penetrated market for MASH diagnostics, driven by an obesity epidemic and new drug approvals, creates a urgent need for non-invasive tests.
The platform's design for longitudinal monitoring positions it ideally as a companion diagnostic for therapy guidance and treatment response tracking.
The underlying technology is extensible to other chronic fibro-inflammatory diseases, offering a substantial long-term expansion runway.

Risk Factors

The novel scientific approach requires robust clinical validation to prove it can accurately identify and stage MASH against the biopsy gold standard.
The company faces significant regulatory and reimbursement hurdles to achieve widespread clinical adoption and payment.
Competition in the non-invasive MASH diagnostic space is intensifying from multiple technological angles.

Competitive Landscape

Hepta competes in the non-invasive MASH diagnostic space against companies using various technologies, including enhanced blood biomarker panels (e.g., GENFIT's NIS4, Quest's NASHNext), imaging-based elastography devices (FibroScan), and imaging AI. Its key differentiation is the use of epigenetic cfDNA analysis combined with AI, claiming a more direct window into liver cell biology compared to protein biomarkers or physical stiffness measurements.

More companies in Diagnostics & Precision Medicine →More companies in United States →